Notable
(FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy · Select Advanced Solid Tumors
Recruitment opened
Also in this update: Trial sites expanded: 0 → 3 locations; Start date changed from estimate of Oct 2026 to Sep 2, 2026
TwoStep Therapeutics, Inc.Phase 1 NCT07814248 Registry history of NCT07814248 on ClinicalTrials.gov (opens the registry)